Montreal Cognitive — Short Screening for Substance Misuse
CRAFFT screening tool for alcohol and substance misuse in adolescents (12–21 years). CRAFFT = Car, Relax, Alone, Forget, Friends, Trouble.
Score interpretation
CRAFFT 0–1. Negative screen for substance misuse disorder.
→ Positive reinforcement. Brief advice on substance avoidance. Reassess annually.
CRAFFT ≥2. Positive screen. Sensitivity 76%, Specificity 94% for substance use disorder.
→ Full assessment of substance use history. AUDIT/DAST for severity. Referral to adolescent CAMHS or substance misuse services. Involve parents/guardians with consent. Safety assessment.
Interpretation bands for the CRAFFT (Adolescent). Apply clinical judgement and local guidance.
References
- Knight JR et al. A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med. 1999;153(6):591-596.
- Cummins LH et al. Diagnostic accuracy of two distinct versions of the CRAFFT in detecting DSM-IV alcohol and other drug use disorders in adolescents. J Subst Abuse Treat. 2003;25(3):173-178.
Related
Curated clinical cross-links plus same-class fallbacks.
- Remifentanil · Opioid (Ultra-Short-Acting)
- Alfentanil · Opioid Analgesic (Ultra-Short Acting)
- Fentanyl (IV — Anaesthesia/ICU) · Opioid Analgesic (Short-Acting)
- Remimazolam · Ultra-Short Acting Benzodiazepine (Procedural Sedation)
- Chloroprocaine hydrochloride · Short-acting ester local anaesthetic
- Mivacurium · Short-acting non-depolarising neuromuscular blocker
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.